PRESS RELEASE published on 01/23/2026 at 07:00, 3 months 20 days ago BB Biotech: Preliminary full-year 2025 results and dividend proposal BB Biotech AG reports strong full-year 2025 results with +34.2% total return in CHF, +37.0% in EUR, and +53.7% in USD, proposes dividend of CHF 2.25 per share at AGM on March 19, 2026 Dividend Proposal Stock Market Full-year Results BB Biotech AG 2025 Performance
BRIEF published on 10/28/2025 at 13:20, 6 months 15 days ago BB Biotech surperforme avec de solides résultats au troisième trimestre 2025 Fusions Et Acquisitions BB Biotech T3 2025 Secteur Des Biotechnologies Indice NASDAQ Biotech
BRIEF published on 10/28/2025 at 13:20, 6 months 15 days ago BB Biotech Outperforms with Strong Q3 2025 Results Biotech Sector M&A BB Biotech Q3 2025 Nasdaq Biotech Index
PRESS RELEASE published on 10/28/2025 at 13:15, 6 months 15 days ago Edison issues report on BB Biotech (BION) Edison issues positive report on BB Biotech (BION) with strong Q325 results, outperforming its benchmark. Sector outlook remains favorable with M&A as key performance driver Edison M&A BB Biotech Outperforming Q325 Results
BRIEF published on 10/24/2025 at 07:05, 6 months 19 days ago BB Biotech AG Releases Interim Report Highlighting Significant Profit Increase Investment Company BB Biotech AG Interim Report Net Profit Increase Drug Developers
BRIEF published on 10/24/2025 at 07:05, 6 months 19 days ago BB Biotech AG publie un rapport intermédiaire soulignant une augmentation significative des bénéfices BB Biotech AG Société D'investissement Augmentation Du Bénéfice Net Rapport Intermédiaire Développeurs De Médicaments
BRIEF published on 10/24/2025 at 07:05, 6 months 19 days ago Surperformance de BB Biotech au troisième trimestre 2025 dans un contexte de reprise sectorielle BB Biotech Performances Du Troisième Trimestre 2025 Indice Nasdaq Biotechnology Thérapies À Base D'ARN Reprise Du Secteur
BRIEF published on 10/24/2025 at 07:05, 6 months 19 days ago BB Biotech's Q3 2025 Outperformance Amid Sector Recovery Sector Recovery BB Biotech Q3 2025 Performance Nasdaq Biotechnology Index RNA-based Therapeutics
PRESS RELEASE published on 10/24/2025 at 07:00, 6 months 19 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes interim report for the first nine months of 2025, reporting CHF 106 mn net profit. More details at report.bbbiotech.ch/Q325 Financial Results Investment Company Net Profit BB Biotech AG Interim Report
PRESS RELEASE published on 10/24/2025 at 07:00, 6 months 19 days ago BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery BB Biotech AG reports strong Q3 2025 performance with portfolio outperforming Nasdaq Biotech Index, driven by solid net profit, key company milestones, and strategic investments BB Biotech AG Interim Report Sector Recovery Q3 2025 Portfolio Outperformance
Published on 05/13/2026 at 00:00, 6 hours 8 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 6 hours 33 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 8 hours 13 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 8 hours 26 minutes ago Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/13/2026 at 04:00, 2 hours 7 minutes ago Siam Piwat redefines global retail with NEXTOPIA, a future prototype where sustainability is a transformative force for business, people, and the planet
Published on 05/12/2026 at 23:47, 6 hours 20 minutes ago Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 7 hours 42 minutes ago Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 9 hours 46 minutes ago Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 10 hours 32 minutes ago AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 18:15, 11 hours 53 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 11 hours 53 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 11 hours 58 minutes ago imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 11 hours 58 minutes ago imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 12 hours 18 minutes ago Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités
